Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lotte E Elshof

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Breast Cancer Research and Treatment|September 15, 2016
Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 womenLotte E Elshof, Michael Schaapveld, Marjanka K Schmidt, et al.
Annals of Surgery|April 5, 2017
Cause-specific Mortality in a Population-based Cohort of 9799 Women Treated for Ductal Carcinoma In SituLotte E Elshof, Marjanka K Schmidt, Emiel J Th Rutgers, et al.
Breast Cancer Research : BCR|March 10, 2017
The method of detection of ductal carcinoma in situ has no therapeutic implications: results of a population-based cohort studyLotte E Elshof, Michael Schaapveld, Emiel J Rutgers, et al.
Nederlands Tijdschrift Voor Geneeskunde|April 14, 2016
[Ductal carcinoma in situ: the balance between over- and undertreatment]Emma J Groen, Lotte E Elshof, Emiel J Th Rutgers, et al.
Breast Cancer Research and Treatment|July 24, 2010
A practical approach to manage additional lesions at preoperative breast MRI in patients eligible for breast conserving therapy: resultsLotte E Elshof, Emiel J Th Rutgers, Eline E Deurloo, et al.
Breast (Edinburgh, Scotland)|September 28, 2016
Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS)Emma J Groen, Lotte E Elshof, Lindy L Visser, et al.
European Journal of Cancer (Oxford, England : 1990)|May 31, 2015
Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD studyLotte E Elshof, Konstantinos Tryfonidis, Leen Slaets, et al.
European Journal of Radiology|September 4, 2013
Does the pretreatment tumor sampling location correspond with metabolic activity on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy?Bas B Koolen, Lotte E Elshof, Claudette E Loo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2018
Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma <i>In Situ</i>-A Nested Case-Control StudyLindy L Visser, Lotte E Elshof, Michael Schaapveld, et al.
British Journal of Cancer|August 19, 2021
Long-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breastMaartje van Seijen, Esther H Lips, Liping Fu, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Breast Cancer Research and Treatment|September 15, 2016
Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 womenLotte E Elshof, Michael Schaapveld, Marjanka K Schmidt, et al.
Annals of Surgery|April 5, 2017
Cause-specific Mortality in a Population-based Cohort of 9799 Women Treated for Ductal Carcinoma In SituLotte E Elshof, Marjanka K Schmidt, Emiel J Th Rutgers, et al.
Breast Cancer Research : BCR|March 10, 2017
The method of detection of ductal carcinoma in situ has no therapeutic implications: results of a population-based cohort studyLotte E Elshof, Michael Schaapveld, Emiel J Rutgers, et al.
Nederlands Tijdschrift Voor Geneeskunde|April 14, 2016
[Ductal carcinoma in situ: the balance between over- and undertreatment]Emma J Groen, Lotte E Elshof, Emiel J Th Rutgers, et al.
Breast Cancer Research and Treatment|July 24, 2010
A practical approach to manage additional lesions at preoperative breast MRI in patients eligible for breast conserving therapy: resultsLotte E Elshof, Emiel J Th Rutgers, Eline E Deurloo, et al.
Breast (Edinburgh, Scotland)|September 28, 2016
Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS)Emma J Groen, Lotte E Elshof, Lindy L Visser, et al.
European Journal of Cancer (Oxford, England : 1990)|May 31, 2015
Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD studyLotte E Elshof, Konstantinos Tryfonidis, Leen Slaets, et al.
European Journal of Radiology|September 4, 2013
Does the pretreatment tumor sampling location correspond with metabolic activity on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy?Bas B Koolen, Lotte E Elshof, Claudette E Loo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2018
Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma <i>In Situ</i>-A Nested Case-Control StudyLindy L Visser, Lotte E Elshof, Michael Schaapveld, et al.
British Journal of Cancer|August 19, 2021
Long-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breastMaartje van Seijen, Esther H Lips, Liping Fu, et al.
Pageof 2